FAP and neoplasm: Statistically significant antitumor activity was observed with tumor growth inhibition (TGI) of 111% and 113% (P < 0.05) in mice treated with 30 or 60 MBq 177Lu-FAP-2286, respectively, relative to the vehicle-treated group (Fig. 5C).